Undoit Medical

Company Overview

Snapshot

Founded in January 2013 by Gershon Goldenberg, Undoit Medical operates with 1–10 employees. The company holds a patent for its technology. In May 2024, Undoit Medical ceased operations.

Business overview

Undoit Medical develops aesthetic treatment solutions, focusing on tattoo removal, stretch marks, melasma, skin rejuvenation, and acne scars. The company's core technology includes Trigation and 3VOTM, patented platforms that utilize controlled mechanical trauma via microneedles, transdermal vehiculation of active ingredients, and surface suction. These systems are designed for user-friendly operation, comprising a standalone unit with a computerized console and handpiece, alongside a disposable kit. Undoit Medical serves the global medical devices, skin care, and dermatology markets, targeting both B2B clients and consumers.

Company Intelligence Q&A

What is the current operational status of Undoit Medical?

Undoit Medical is currently non-active, having ceased operations in May 2024.

What is Undoit Medical's primary focus in the aesthetic treatment market?

Undoit Medical develops solutions for tattoo removal, stretch marks, melasma, skin rejuvenation, and acne scars.

Can you describe Undoit Medical's core technology?

Undoit Medical developed Trigation and 3VOTM, patented platform technologies for aesthetic treatments. These systems combine evenly controlled mechanical trauma to the skin using microneedles, transdermal vehiculation of active ingredients, and simultaneous surface suction.

Does Undoit Medical hold any patents for its technology?

Yes, Undoit Medical holds a patent for its Trigation platform technology.

What markets does Undoit Medical target with its products?

Undoit Medical targets global markets, serving both B2B clients and consumers within the medical devices, skin care, and dermatology sectors.